Fibrin-Binding uPA Polypeptide for Targeted Clot Dissolution
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current thrombolytic agents like rtPA are unstable, difficult to produce, and can cause systemic side effects due to nonspecific binding, while broad thrombin inhibitors affect multiple coagulation processes, leading to complications such as bleeding and reduced effectiveness.
Innovation Solution
A novel polypeptide comprising a fibrin-binding domain derived from a llama antibody (VHH) and a urokinase-type plasminogen activator (uPA) domain, specifically targeting fibrin for localized clot degradation, enhancing stability and specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If recombinant tissue plasminogen activator (rtPA) is used as a thrombolytic agent, then clot dissolution efficacy is improved, but stability and ease of production deteriorate
Solution Approach 1:
The invention segments the thrombolytic function from the complex rtPA structure by using a simplified uPA domain combined with a fibrin-binding VHH domain. This segmentation maintains clot dissolution efficacy through the uPA-plasminogen activation pathway while eliminating the production difficulties associated with full-length rtPA's complex structure.
Solution Approach 2:
The invention extracts only the essential functional domains needed for thrombolysis: the catalytic uPA domain for plasminogen activation and the fibrin-targeting VHH domain for localization. This extraction removes the unstable and difficult-to-produce portions of rtPA while retaining therapeutic efficacy.
2Object-affected harmful factors
If broad thrombin inhibitors are used to prevent clotting, then clot formation is reduced, but bleeding risk and effectiveness deteriorate
Solution Approach 1:
The invention applies local quality by directing the thrombolytic action specifically to the clot site through the fibrin-binding VHH domain. The uPA-fibrin complex locally activates plasminogen to plasmin at the thrombus location, dissolving clots without systemically inhibiting coagulation pathways, thereby avoiding bleeding complications.
Solution Approach 2:
The invention uses the fibrin-binding VHH domain as an intermediary that delivers the uPA catalyst specifically to the fibrin clot. This targeted delivery mechanism ensures that plasminogen activation occurs only at the clot site rather than throughout the bloodstream, preventing systemic anticoagulation and bleeding risks.
3Measurement precision
If thrombin generation is broadly monitored in plasma, then coagulation process estimation is improved, but specificity for localized clot dissolution deteriorates
Solution Approach 1:
The invention transitions from broad plasma-based thrombin generation monitoring to localized clot-targeted therapy. The VHH-uPA fusion protein specifically binds to fibrin at the clot site, delivering thrombolytic activity locally rather than systemically, thereby achieving both measurement precision in identifying clot presence and localized action for dissolution.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polypeptide achieves efficient and targeted clot dissolution with minimal systemic effects, maintaining hemostatic balance and reducing the risk of bleeding, while being easier to produce and more stable than rtPA.
Implementation Method 1
an immunoglobulin single variable domain able to bind to fibrin
Implementation Method 2
a urokinase-type plasminogen activator (uPA) domain
Data Source
Figure 1A~1F(iii)
Figure 2A(i)~3F
Figure 4A(i)~4C(iii)
AI summary
The current invention relates to a polypeptide comprising an immunoglobulin single variable domain and an urokinase-type plasminogen activator (uPA) domain wherein the immunoglobulin single variable domain is able to bind to fibrin via a fibrin-binding domain.